Form 4: Tandem Diabetes Care Executive Susan Morrison Reports Stock Transactions
SEC Form 4 Filing
EVP & Chief Admin. Officer of Tandem Diabetes Care, Susan Morrison, reports the vesting of restricted stock units and subsequent tax withholding, resulting in a net increase in her holdings of common stock.
Summary
- On February 18, 2025, Susan Morrison, EVP & Chief Admin. Officer of Tandem Diabetes Care, reported transactions involving common stock and restricted stock units (RSUs).
- Morrison acquired shares through the vesting of RSUs granted under the company's 2013 and 2023 Stock Incentive Plans.
- A portion of the shares acquired upon vesting were withheld by Tandem Diabetes Care to satisfy tax withholding requirements.
- Specifically, 56, 161 and 510 shares were withheld at a price of $33.47.
- After these transactions, Morrison directly owns 26,313 shares of Tandem Diabetes Care common stock and 7,515 derivative securities.
Sentiment
Score: 5
Explanation: This Form 4 filing is a routine disclosure of executive stock transactions and does not inherently convey positive or negative sentiment. It reflects the normal course of executive compensation.
Positives
- The vesting of RSUs indicates that performance milestones or time-based vesting schedules have been met.
- Morrison's continued direct ownership of 26,313 shares suggests a continued alignment with the company's success.
Industry Context
Executive stock transactions are a common occurrence in publicly traded companies and are regularly monitored by investors for insights into management's perspective on the company's performance and future prospects. This filing is a routine disclosure and doesn't necessarily indicate a significant shift in sentiment.
Comparison to Industry Standards
- Executive compensation packages in the medical device industry, including companies like Medtronic, Abbott, and Boston Scientific, often include a mix of salary, stock options, and restricted stock units.
- The vesting schedules and terms of Tandem Diabetes Care's RSU grants appear to be fairly standard compared to those offered by its peers.
- The tax withholding practices are also consistent with standard procedures for equity compensation.
Stakeholder Impact
- The transactions have a minimal direct impact on shareholders, as they primarily involve the vesting of previously granted equity awards.
- Employees who are also RSU recipients may view the vesting as a positive sign of the company's performance and their own contributions.
Key Dates
| Date | Description |
|---|---|
| May 18, 2021 | Date of RSU award pursuant to the 2013 Plan. |
| May 15, 2022 | First vesting date (25%) for RSU awarded on May 18, 2021. |
| May 25, 2022 | Date of RSU award pursuant to the 2013 Plan. |
| May 15, 2023 | First vesting date (33%) for RSU awarded on May 25, 2022. |
| May 25, 2023 | Date of RSU award pursuant to the 2023 Plan. |
| May 15, 2024 | First vesting date (33%) for RSU awarded on May 25, 2023. |
| February 18, 2025 | Date of reported transactions (RSU vesting and tax withholding). |
| February 20, 2025 | Date of signature for the Form 4 filing. |
Keywords
Tandem Diabetes Care, Susan Morrison, Form 4, RSU, Stock Incentive Plan, Beneficial Ownership, Executive Compensation, Stock Options, Vesting, Tax Withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.